HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In-San Kim Selected Research

phenylalanyl-arginyl-arginine

1/2021Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


In-San Kim Research Topics

Disease

112Neoplasms (Cancer)
01/2022 - 10/2002
10Neoplasm Metastasis (Metastasis)
01/2021 - 10/2002
10Breast Neoplasms (Breast Cancer)
11/2020 - 05/2008
10Lung Neoplasms (Lung Cancer)
01/2019 - 09/2003
8Melanoma (Melanoma, Malignant)
10/2021 - 03/2006
6Inflammation (Inflammations)
01/2020 - 10/2003
6Atherosclerotic Plaque (Atheroma)
01/2020 - 06/2008
6Atherosclerosis
01/2020 - 10/2008
4Sepsis (Septicemia)
01/2020 - 04/2014
4Carcinogenesis
10/2017 - 01/2007
4Cadaver (Cadavers)
09/2009 - 04/2008
4Fibrosis (Cirrhosis)
06/2008 - 10/2002
3Thrombosis (Thrombus)
01/2018 - 06/2007
3Urinary Bladder Neoplasms (Bladder Cancer)
10/2016 - 01/2007
3Colonic Neoplasms (Colon Cancer)
02/2015 - 09/2008
3Genetic Predisposition to Disease (Genetic Predisposition)
04/2008 - 10/2003
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2008 - 10/2003
3Hereditary Corneal Dystrophies
10/2007 - 03/2002
3Adenocarcinoma
01/2007 - 10/2003
2Colorectal Neoplasms (Colorectal Cancer)
10/2021 - 01/2021
2Hypoxia (Hypoxemia)
01/2021 - 02/2003
2Pancreatic Neoplasms (Pancreatic Cancer)
11/2020 - 01/2019

Drug/Important Bio-Agent (IBA)

39Peptides (Polypeptides)IBA
10/2021 - 03/2004
23Pharmaceutical PreparationsIBA
10/2021 - 02/2008
23Proteins (Proteins, Gene)FDA Link
01/2021 - 03/2002
21Doxorubicin (Adriamycin)FDA LinkGeneric
10/2021 - 08/2003
12glycol-chitosanIBA
02/2014 - 08/2003
10Transforming Growth Factor beta (TGF-beta)IBA
10/2010 - 03/2002
9Biomarkers (Surrogate Marker)IBA
10/2021 - 10/2003
9ProdrugsIBA
01/2021 - 02/2015
8LigandsIBA
10/2021 - 01/2008
7Ferritins (Ferritin)IBA
10/2021 - 03/2016
7IntegrinsIBA
07/2018 - 01/2008
6CaspasesIBA
10/2021 - 12/2009
6Coloring Agents (Dyes)IBA
01/2019 - 02/2010
6Small Interfering RNA (siRNA)IBA
10/2017 - 02/2008
6Drug CarriersIBA
11/2011 - 09/2006
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 10/2003
5Therapeutic UsesIBA
10/2021 - 02/2008
5Caspase 3 (Caspase-3)IBA
01/2019 - 02/2015
5Interleukin-4 Receptors (Interleukin 4 Receptor)IBA
03/2016 - 10/2008
5Heparin (Liquaemin)FDA LinkGeneric
12/2008 - 09/2006
5Transforming Growth Factor beta1 (TGF beta 1)IBA
05/2007 - 10/2002
4Cisplatin (Platino)FDA LinkGeneric
12/2021 - 04/2008
4Immune Checkpoint InhibitorsIBA
10/2021 - 01/2021
4Antineoplastic Agents (Antineoplastics)IBA
10/2021 - 05/2009
4CytokinesIBA
01/2021 - 07/2010
4Poloxamer (Poloxamer 407)IBA
01/2020 - 07/2015
4Liposomes (Liposome)IBA
01/2019 - 04/2011
4MicellesIBA
10/2017 - 11/2007
4PolymersIBA
10/2017 - 02/2007
4Fibronectins (Fibronectin)IBA
06/2016 - 03/2002
4cysteinyl- glutaminyl- arginyl- prolyl- prolyl- arginineIBA
01/2015 - 12/2010
4PhosphatidylserinesIBA
01/2015 - 09/2008
4Fluorescein (Funduscein)FDA LinkGeneric
11/2008 - 08/2003
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2022 - 08/2004
3Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
01/2022 - 03/2013
3rho-Associated KinasesIBA
11/2021 - 01/2018
3liposomal doxorubicin (Doxil)FDA Link
10/2021 - 04/2011
3Membrane Proteins (Integral Membrane Proteins)IBA
12/2020 - 04/2016
3EnzymesIBA
10/2020 - 11/2011
3AntigensIBA
11/2019 - 10/2003
3CollagenIBA
10/2018 - 10/2007
3DisulfidesIBA
10/2017 - 07/2012
3Deoxycholic Acid (Sodium Deoxycholate)IBA
10/2017 - 02/2008
3Tumor Biomarkers (Tumor Markers)IBA
12/2016 - 01/2016
3KLA peptideIBA
10/2016 - 06/2008
3Angiogenesis InhibitorsIBA
04/2016 - 12/2008
3Messenger RNA (mRNA)IBA
07/2015 - 10/2002
3Hyaluronic Acid (Hyaluronan)IBA
01/2015 - 10/2003
3CamptothecinIBA
01/2015 - 05/2008
3Paclitaxel (Taxol)FDA LinkGeneric
05/2014 - 03/2006
3Histones (Histone)IBA
01/2014 - 12/2010
3Extracellular Matrix ProteinsIBA
02/2012 - 03/2002
32- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
11/2011 - 05/2008
3Fluorescein-5-isothiocyanate (FITC)IBA
10/2011 - 08/2003
3Radioisotopes (Radionuclides)IBA
12/2010 - 02/2007
3ChitosanIBA
09/2010 - 08/2003
3monomethoxypolyethylene glycol (MPEG)IBA
06/2010 - 11/2007
3poly(beta-amino ester)IBA
06/2010 - 11/2007
3Guanosine Diphosphate (GDP)IBA
01/2010 - 10/2003
3Cell Adhesion MoleculesIBA
04/2008 - 03/2002
3Desoxycorticosterone Acetate (DOCA)FDA Link
06/2007 - 09/2006
3Glucose (Dextrose)FDA LinkGeneric
02/2007 - 03/2003
2AcidsIBA
01/2022 - 11/2015
2Biocompatible Materials (Biomaterials)IBA
01/2022 - 08/2011
2Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
12/2021 - 01/2021
2microplasminIBA
10/2021 - 01/2018
2Apoptosis Regulatory ProteinsIBA
10/2021 - 10/2017
2Hemostatics (Antihemorrhagics)IBA
10/2021 - 01/2018
2Cathepsin BIBA
01/2021 - 02/2014
2AnticoagulantsIBA
01/2021 - 03/2013
2Fluorescent Dyes (Fluorescent Probes)IBA
01/2020 - 12/2010
2Protein CIBA
01/2020 - 11/2015

Therapy/Procedure

49Therapeutics
12/2021 - 10/2003
16Immunotherapy
12/2021 - 09/2012
13Drug Therapy (Chemotherapy)
01/2019 - 02/2007
4Intravenous Injections
10/2020 - 02/2007
4Intravenous Administration
01/2020 - 01/2006
4Radiotherapy
01/2019 - 08/2015